JP2008507550A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507550A5
JP2008507550A5 JP2007522782A JP2007522782A JP2008507550A5 JP 2008507550 A5 JP2008507550 A5 JP 2008507550A5 JP 2007522782 A JP2007522782 A JP 2007522782A JP 2007522782 A JP2007522782 A JP 2007522782A JP 2008507550 A5 JP2008507550 A5 JP 2008507550A5
Authority
JP
Japan
Prior art keywords
disorder
azabicyclo
hexane
racemic
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025974 external-priority patent/WO2006012474A1/en
Publication of JP2008507550A publication Critical patent/JP2008507550A/ja
Publication of JP2008507550A5 publication Critical patent/JP2008507550A5/ja
Pending legal-status Critical Current

Links

JP2007522782A 2004-07-22 2005-07-21 神経系障害及び状態の処置方法 Pending JP2008507550A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020304P 2004-07-22 2004-07-22
PCT/US2005/025974 WO2006012474A1 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (2)

Publication Number Publication Date
JP2008507550A JP2008507550A (ja) 2008-03-13
JP2008507550A5 true JP2008507550A5 (https=) 2008-08-21

Family

ID=35149631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522782A Pending JP2008507550A (ja) 2004-07-22 2005-07-21 神経系障害及び状態の処置方法

Country Status (14)

Country Link
US (2) US20060020015A1 (https=)
EP (1) EP1773320A1 (https=)
JP (1) JP2008507550A (https=)
KR (1) KR20070034126A (https=)
CN (1) CN101410106A (https=)
AU (1) AU2005266994A1 (https=)
BR (1) BRPI0512186A (https=)
CA (1) CA2574310A1 (https=)
IL (1) IL180731A0 (https=)
MX (1) MX2007000853A (https=)
NO (1) NO20070912L (https=)
RU (1) RU2007102292A (https=)
WO (1) WO2006012474A1 (https=)
ZA (1) ZA200700578B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
MX2007000851A (es) * 2004-07-22 2007-03-26 Wyeth Corp Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
US8000005B2 (en) * 2006-03-31 2011-08-16 Prysm, Inc. Multilayered fluorescent screens for scanning beam display systems
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
GR72713B (https=) * 1976-09-15 1983-12-01 American Cyanamid Co
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
EP0114033B1 (de) * 1982-12-21 1988-10-12 Ciba-Geigy Ag Substituierte Azabicycloalkane, ihre Verwendung, pharmazeutische Präparate, welche diese Verbindungen enthalten, und Verfahren zur Herstellung dieser Verbindungen
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
EP1864967A1 (en) * 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions

Similar Documents

Publication Publication Date Title
Thase Antidepressant treatment of the depressed patient with insomnia
JP2019031502A5 (https=)
CN119095595A (zh) 用于治疗睡眠紊乱的5-meo-dmt
TW201011007A (en) Treatment for neurological and mental disorders
JP2023509720A (ja) 認知障害の予防及び療法
CN119278036A (zh) 用于治疗睡眠紊乱的5-MeO-DMT
JP2020514313A5 (https=)
MX2010002890A (es) 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.
JP2008507550A5 (https=)
JP2005508872A5 (https=)
RU2007102292A (ru) Способ лечения расстройств и заболеваний нервной системы
RU2007102291A (ru) Способ лечения расстройств и заболеваний нервной системы
Kamal et al. The effect of sleep hygiene and relaxation Benson on improving the quality of sleep among health failure patients: A literature review
RU2007102290A (ru) Способ лечения нарушений и заболеваний нервной системы
Kamal Potential effectiveness of sleep hygiene and relaxation Benson in improving the quality of sleep in patients with heart failure: Literature review
JP2026510117A (ja) うつ状態の神経調節と薬理学的治療とを組み合わせたシステム、デバイス、及び方法
JPWO2019157273A5 (https=)
US20230381168A1 (en) Adjunctive therapy for depression
Crabb Sleep disorders in Parkinson's disease: the nursing role
Clayton et al. Combination therapy in fibromyalgia
Moldofsky et al. Sleep and its potential role in chronic pain and fatigue
Bean et al. 1099 Sleep Restriction Leads To Greater Next-day Anxiety: The Moderating Role Of Anxiety And Depression
Suzuki et al. Nocturnal Disturbances in Patients with Parkinson’s Disease
CN118973571A (zh) 认知功能障碍的治疗
WO2003014114A3 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors